This article is the result of a conference held in Malmö. May 2022 By ASSET Consortium (www.asset.Healthcare) discussed key factors and opportunities for the integration of artificial intelligence (AI) in early type 1 diabetes screening. This publication highlights the need for accuracy in risk assessments and individual monitoring plans. The article also highlights the overall feasibility and cost-effectiveness of screening.ofThe ASSET consortium is funded and coordinated by the Swedish innovation agency VINNOVA. Diamid Medical.
“and Diamid Medical Co., Ltd. Investing in AI and precision medicine therapies Diamide “Currently in Phase 3 development, we believe there is great potential for ways to delay and ultimately prevent type 1 diabetes through safe and precise therapeutic interventions.” Wolf HaneliusCEO of Diamid Medical. “The ASSET consortium and the broader network of type 1 diabetes experts are doing a great job in paving the way for how these efforts can be implemented.”
Based on extensive research and clinical experience, the authors discuss the untapped potential of AI in identifying and stratifying individuals at risk for type 1 diabetes. An article in Diabetologia delves into the practicalities of leveraging AI to analyze vast data repositories with the goal of refining screening strategies and enhancing early detection and preventive care for type 1 diabetes.
“AI shows promise in predicting diseases including diabetes.” paul pettersson, Professor of Real-Time Systems at Maladalen University. “Machine learning algorithms can be used to analyze large data sets, identify patterns, and make predictions based on the information the algorithm learns from the data. In the context of diabetes prediction, AI can be applied to Analyzes different types of data, including medical records, genetic information, and lifestyle factors to predict when and how likely you will develop type 1 diabetes. ”
Åke Lahnmark, Professor of Experimental Diabetes at Lund University CRC, said: “Through the TEDDY study, we now have a better understanding of what triggers autoimmune reactions, which will help us analyze the subsequent progression of the disease to clinical onset. This highlights the need for AI to do this.” Mr. Malmö and his ASSET consortium researchers. “The progression of type 1 diabetes is highly individualized, and AI will be important in personalizing preventive treatment.”
“Type 1 diabetes is the second most common chronic disease among children worldwide. Sweden And its incidence is increasing not only in the Nordic countries but around the world.” Gunfor Thunder,Associate Professor Queen Sylvia Children’s Hospital, Sahlgrenska University Hospital. “This is a disease that has serious implications at both the individual and family level, and at societal costs. The ultimate goal is to prevent type 1 diabetes. Currently, large amounts of data from existing databases are available. Data is available for the ASSET study. AI techniques will allow us to identify predictive factors and provide potential preventive treatments, which makes the ASSET study unique and extremely important.”
The authors conclude that AI has the potential to revolutionize screening for type 1 diabetes. This commentary will help healthcare providers, regulators, and payers recognize and support advances in this field, encourage further research and discussion on this timely and important topic, and identify breakthrough developments in this field. It is a call to action to lead to.
This article can be accessed from: https://link.springer.com/article/10.1007/s00125-024-06089-5#rightslink
About assets
Innovation environment ASSET (AI for Sustainable Prevention of Autoimmunity in Society – www.asset.healthcare) is using artificial intelligence (AI) to help assess an individual’s risk of developing type 1 diabetes (T1D). Develop and evaluate new algorithms based on , and the likelihood of responding to various treatments. Data from cohort studies such as TEDDY (Environmental Determinants of Diabetes in Youth); Diamid Medical Co., Ltd. clinical trial Diamide® In addition, sources such as the National Diabetes Registry constitute the initial training dataset for the algorithm. Although T1D will be the pilot project for this program, the goal is to include other autoimmune diseases that are strongly associated with T1D, such as celiac disease (gluten intolerance) and autoimmune thyroiditis (an inflammatory disease of the thyroid). The goal is to extend functionality to other indications. In parallel, ASSET will study the organizational, economic and legal preconditions and consequences of applying this approach as a precision medicine tool in the Swedish healthcare system. September 2021has a duration of five years and is funded through the Swedish innovation agency VINNOVA.
The ASSET consortium focuses on AI, lund university, Sahlgrenska University Hospital, Swedish National Diabetes Register, leading healthcare foundation and Diamid MedicalProject Coordinator.
Website: https://www.asset.healthcare
about Diamid Medical
Diamid Medical Developing precision medicine therapies for the prevention and treatment of type 1 diabetes, Lada (Subclinical autoimmune diabetes in adults). Diamide® Antigen-specific immunotherapy to maintain endogenous insulin production. The confirmatory Phase III trial, DIAGNODE-3, is actively recruiting patients with recent onset type 1 diabetes in eight European countries and the United States. Significant results have previously been shown in a large, genetically predefined group of patients in a large meta-analysis and in our European Phase IIb trial. Diamide® It was administered directly into the lymph nodes of children and young adults who had recently been diagnosed with type 1 diabetes. A biomanufacturing facility has been established in Umeå for the production of recombinant GAD65 protein, the active ingredient in antigen-specific immunotherapy. Diamide®. Diamid Medical Also developed GABA-based investigational drug Remigen® As a component in the treatment of metabolic diseases. Diamid Medical I am a major shareholder in a stem cell company. NextCell Pharma AB At an artificial intelligence company Mainly AI AB.
Diamid Medical Co., Ltd. B shares are traded on the Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB He is our certified advisor.
For more information, please contact us below.
Wolf Hanelius
Representative Director and President
Phone: +46 736 35 42 41
Email: ulf.hannelius@diamyd.com
Diamid Medical AB (Publishing)
Box 7349, SE-103 90 stockholm sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
Email: info@diamyd.com Number: 556242-3797 Website: https://www.diamyd.com
This information was provided by the contact person listed above for publication. February 14, 202415.50 Central European Time.
https://news.cision.com/diamyd-medical-ab/r/publication-in-diabetologia-highlights-ai-s-potential-for-type-1-diabetes-screening,c3928766
https://mb.cision.com/Main/6746/3928766/2605041.pdf
(c) 2024 Decision.All rights reserved, source Press release – English
